BioNTech (BNTX) Stock Surges 22% on Moderna Cancer Vaccine Trial Win
TLDR
- BioNTech stock surged 22% to $113.12, its biggest single-day gain since April 2023
- The rally was sparked by positive Phase 3 trial data for Moderna and Merck’s personalized cancer vaccine, intismeran autogene, combined with Keytruda
- Leerink Partners analyst Daina Graybosch says the gains are likely to fade, citing poor read-through for BioNTech specifically
- BioNTech’s own cancer vaccine pipeline has moved slower than Moderna’s, with a key candidate paused in late 2025
- The company is also dealing with a leadership transition and weak post-pandemic revenue
BioNTech stock jumped 22% on Wednesday to $113.12, posting its largest single-day gain since April 2023. The move came after Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine.
The trial, called INTerpath-001, showed that intismeran autogene combined with Merck’s Keytruda was more effective at preventing melanoma recurrence than Keytruda alone. The news sent Moderna stock nearly tripling, while Merck added over 12%.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
